India’s Biocon Biologics says biosimilars put revenue on $1 billion trajectory, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Biocon Biologics, which acquired the biosimilars business of US-based Viatris in a $3.34 billion deal, informed its annual revenue rose 61 per cent year-on-year to 55.84 billion rupees, reflecting one quarter of consolidated figures after the buy, compared to 34.64 billion rupees the previous year., Biocon Biologics, which acquired the biosimilars business of US-based Viatris in a $3.34 billion deal, informed its annual revenue rose 61 per cent year-on-year to 55.84 billion rupees, reflecting one quarter of consolidated figures after the buy, compared to 34.64 billion rupees the previous year., , Read More